TY - JOUR
T1 - Hypogonadism, frailty, and postoperative outcomes among men undergoing partial nephrectomy
AU - Lazarovich, Alon
AU - Greenberg, Daniel R.
AU - Rhodes, Stephen P.
AU - Bhambhvani, Hriday P.
AU - Gago, Luis C.
AU - Patel, Hiten D.
AU - Brannigan, Robert E.
AU - Shoag, Jonathan E.
AU - Halpern, Joshua A.
N1 - Publisher Copyright:
© (2024), (Canadian Journal of Urology). All rights reserved.
PY - 2024
Y1 - 2024
N2 - Introduction: To determine the prevalence ofhypogonadism in men undergoing partial nephrectomy (PN) and whether hypogonadism and frailty are associated with adverse postoperative outcomes. Materials and methods: We identified men undergoing PN between 2012–2021 using the Merative Marketscan database. Patients were considered to have hypogonadism if diagnosed within 5 years prior to PN. Frailty was determined using the Hospital Frailty Risk Score (HFRS). Length of stay (LOS), complications, ED visits, and inpatient readmissions were compared. Sub-group analysis of men with hypogonadism was performed to determine if testosterone replacement therapy (TRT) improved clinical outcomes. Results: Among 9, 105 men who underwent PN, 809 (8.9%) were hypogonadal prior to PN. Hypogonadal men were significantly more frail compared to eugonadal men (HFRS score: median 6.7, IQR 4.1–10.1 vs. median 5.6, IQR 3.3–8.8, p < 0.001). However, there was no significant difference in LOS following PN nor in 90-day postoperative complications, ED visits, or inpatient readmission between men with and without hypogonadism. However, intermediate- and high-risk frailty were associated with increased risk of 90-day ED visits and 90-day inpatient readmission compared to low-risk patients. Among high-risk men with hypogonadism, TRT was associated with decreased risk of 90-day ED visits (p = 0.04). Conclusions: Frailty was associated with postoperative outcomes following PN. Hypogonadism was associated with frailty, and treatment of hypogonadal men with TRT was associated with reduction in post-operative risk. These findings suggest a role for frailty assessment, and possibly testosterone screening, in men undergoing PN.
AB - Introduction: To determine the prevalence ofhypogonadism in men undergoing partial nephrectomy (PN) and whether hypogonadism and frailty are associated with adverse postoperative outcomes. Materials and methods: We identified men undergoing PN between 2012–2021 using the Merative Marketscan database. Patients were considered to have hypogonadism if diagnosed within 5 years prior to PN. Frailty was determined using the Hospital Frailty Risk Score (HFRS). Length of stay (LOS), complications, ED visits, and inpatient readmissions were compared. Sub-group analysis of men with hypogonadism was performed to determine if testosterone replacement therapy (TRT) improved clinical outcomes. Results: Among 9, 105 men who underwent PN, 809 (8.9%) were hypogonadal prior to PN. Hypogonadal men were significantly more frail compared to eugonadal men (HFRS score: median 6.7, IQR 4.1–10.1 vs. median 5.6, IQR 3.3–8.8, p < 0.001). However, there was no significant difference in LOS following PN nor in 90-day postoperative complications, ED visits, or inpatient readmission between men with and without hypogonadism. However, intermediate- and high-risk frailty were associated with increased risk of 90-day ED visits and 90-day inpatient readmission compared to low-risk patients. Among high-risk men with hypogonadism, TRT was associated with decreased risk of 90-day ED visits (p = 0.04). Conclusions: Frailty was associated with postoperative outcomes following PN. Hypogonadism was associated with frailty, and treatment of hypogonadal men with TRT was associated with reduction in post-operative risk. These findings suggest a role for frailty assessment, and possibly testosterone screening, in men undergoing PN.
KW - frailty
KW - hypogonadism
KW - partial nephrectomy
KW - testosterone
UR - http://www.scopus.com/inward/record.url?scp=85212890030&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85212890030&partnerID=8YFLogxK
M3 - Article
C2 - 39675036
AN - SCOPUS:85212890030
SN - 1195-9479
VL - 31
SP - 12045
EP - 12052
JO - Canadian Journal of Urology
JF - Canadian Journal of Urology
IS - 6
ER -